BMWS25

At the most recent edition of the Biomanufacturing World Summit series we sat down with Kawa Chiu of Abdera Therapeutics to talk about advances in targeted radiotherapeutics and some of the supply chain implications of recent developments. Radiotherapeutics differs from traditional radiation therapy in that an antibody or small molecule delivers radiation internally to the cancer cells, sparing healthy tissue that might be damaged by externally applied radiation. A lot of great progress is being made in the sophistication and efficacy of this form of treatment —especially through a biologics approach— but it does come with challenges on sourcing and delivering treatments that are dangerous to handle without special care, and whose shelf-live is measured in half-lives. For a fascinating look at one of the forefronts of medicine, give this episode a listen!